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Idiopathic osteonecrosis of femoral head (ION) is a painful disorder that progresses to collapse of the femoral head
and destruction of the hip joint. Although its precise pathology remains unknown, the loss of blood supply causing the
loss of living bone-forming cells is a hallmark of the pathophysiology of osteonecrosis. Transplantation of multipotent
mesenchymal stromal cells (MSCs) is a promising tool for regenerating the musculoskeletal system. The aim of the
present study was to assess the safety and efficacy of transplantation of cultured autologous bone marrow-derived
MSCs mixed with b-tricalcium phosphate (b-TCP) in combination with vascularized bone grafts for the treatment of
advanced stage ION in a clinical trial. Ten patients with stage 3 ION were enrolled in this study. Autologous bone
marrow-derived MSCs were cultured with autologous serum, and cells (0.5–1.0·108) were transplanted after mixing
with b-TCP granules in combination with vascularized iliac bone grafts. Patients were assessed 24 months after
treatment. The primary and secondary endpoints were progression of the radiological stage and changes in bone
volume at the femoral head, and clinical score, respectively. Nine of ten patients completed the protocol, seven of
whom remained at stage 3, and the remaining two cases progressed to stage 4. The average bone volume increased
from 56.5–8.5 cm3 to 57.7–10.6 cm3. The average clinical score according to the Japan Orthopaedic Association
improved from 65.6–25.5 points to 87.9–19.0 points. One severe adverse event was observed, which was not
related to the clinical trial. Although the efficacy of cell transplantation was still to be determined, all procedures were
successfully performed and some young patients with extensive necrotic lesions with pain demonstrated good bone
regeneration with amelioration of symptoms. Further improvements in our method using MSCs and the proper
selection of patients will open a new approach for the treatment of this refractory disease.
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Idiopathic osteonecrosis of femoral head (ION) is apainful disorder that progresses to collapse of the femoral
head and symptomatic osteoarthritis of the hip joint.1,2 This
disease mainly affects individuals aged 30–40 years of age.3
ION includes steroid-induced, alcoholism-related, and true
idiopathic conditions. The precise pathological mechanism of
ION remains unknown, however, macro- or microscopic
obstruction of blood supply to the femoral head is considered
to be a hallmark of this condition, which causes the necrosis
of bone-forming cells. Bone tissues without bone-forming
cells gradually lose their mechanical properties and eventu-
ally collapse, causing articular surface deformities.1–3
Several staging and classification systems have been ap-
plied to diagnose ION, and the system proposed by the
Specific Disease Investigation Committee (SDIC) has been
used in Japan, which is a modified version of the system
proposed by the Association Research Circulation Osseous
(ARCO) Committee.4 This staging system includes stage 1
(specific findings of osteonecrosis are observed on magnetic
resonance imaging [MRI], bone scintigram, or histology, not
on X-ray images), stage 2 (demarcating sclerosis is seen
without collapse of the femoral head), stage 3 (collapse of
the femoral head, including the crescent sign, is seen
without joint-space narrowing. Mild osteophyte formation
of the femoral head or acetabulum may be seen), and stage 4
(osteoarthritic changes are seen). Stage 3 was subdivided
into stage 3A (collapse of the femoral head being less than
3mm) and stage 3B (collapse of the femoral head being
3mm or greater).4 Although the natural history of ION
depends on the etiological background of each case, this
condition is considered to be a progressive disease from the
early stage (stage 1), with minimum necrotic areas found
only by MRI, to the advanced stage (stage 4), with painful
osteoarthritis of the hip joint.4,5 Regarding the surgical
treatment of patients at early stages (stage 1 or 2), core
decompression has been widely used to decompress ele-
vated pressure in the femoral head.5–7 Although this pro-
cedure may be effective for some patients, the results are
unpredictable.7 Total hip arthroplasty (THA) is the only way
to treat patients at the terminal stage (stage 4).1,3 The sur-
vival rate of THA has markedly improved owing to the
advancement of materials and surgical technology.3 How-
ever, THA should be avoided as much as possible, because
patients with ION are relatively young, therefore, joint-
preserving treatment for patients at stage 3 is a critical issue.
Sugioka’s rotational osteotomy, which replaces the weight-
bearing area with intact bone tissues, has been used for stage
3 patients and was shown to be effective in some patients.8
However, the application of this surgery is limited for pa-
tients with intact areas.9 Because the loss of blood supply
and bone-forming cells are causative for this condition,
grafting vascularized bones is a theoretically reasonable way
to treat this condition.10 Clinical results appear to depend on
the size of the necrotic area and the prolonged period re-
quired to generate new bone tissues,10 possibly due to the
decreased number of bone-forming cells.11,12
The application of concentrated bone marrow cells
(BMCs) to ION was initiated by Hernigou.13 He invented a
method to transplant BMCs after core decompression and
performed it on a large number of patients at early stages.
The effect of transplantation was not clear because of the
lack of controls in his studies.14 Gangji et al. conducted
prospective randomized studies and reported that the ap-
plication of concentrated BMCs significantly delayed pro-
gression of the disease,15,16 and its effect continued 5 years
after transplantation.16 The clinical results of this method
depended at least partly on the number of osteogenic cells in
aspirated BMCs, which could not be controlled.11
Multipotent mesenchymal stromal cells (MSCs) are
promising materials for regenerating the musculoskeletal
system.17,18 MSCs are defined as plastic dish-adherent cells
that can be differentiated to cells in osteogenic, chondro-
genic, and adipogenic lineages in vitro.19,20 MSCs may also
be able to differentiate to vascular endothelial cells.21 They
are found in several different tissues,17 among which bone
marrow stroma is a representative home of MSCs; therefore,
the therapeutic effect of BMCs for ION may depend on the
effect of MSCs. The application of MSCs expanded in vitro
for ION was considered to overcome the issue of the un-
stable number of BMC treatment, and Zhao conducted a
prospective randomized trial using in vitro-expanded MSCs
and reported that cultured MSC transplantation in combi-
nation with core decompression surgery was effective in
delaying and avoiding femoral head collapse.22 Although
these findings suggest the promising role of MSCs on ION,
this was also shown to be ineffective for patients at ad-
vanced stages such as stage 3.22
We previously designed a treatment with a combination of
MSCs and vascularized bone grafts to apply MSCs for ad-
vanced stages, and performed a preclinical study using an
animal model.23 Based on the promising results of that study,
we proceeded to clinical trials and herein we report the result.
Materials and Methods
Study design
This study was a prospective, open-labeled, proof-
of-concept clinical trial conducted in the Kyoto University
Hospital. Patient registration and data management were
performed in the Department of Clinical Trial Design and
Management, Translational Research Center, KyotoUniversity
Hospital. This clinical study was registered to the UMIN
Clinical Trials Registry (UMIN000001601). The study proto-
col was approved by the Ethics Committee of Kyoto University
Graduate School and Faculty of Medicine, Guidelines on
Clinical Research using Human Stem Cells of Ministry of
Health, Labour and Welfare, Japan (www.mhlw.go.jp/bunya/
kenkou/iryousaisei06/pdf/111201_ 1.pdf) and was conducted
according to the Declaration of Helsinki. Results were evalu-
ated 24 months after the treatment, and the primary endpoint
was the progression of the radiographic stage and the secondary
endpoint was bone volume changes evaluated by computed
tomography (CT), and clinical score.
Patients eligibility
Eligibility criteria were between 20 and 50 years of age
and the presence of necrotic stage 3A or 3B according to the
radiographic stage system by the SDIC.4 The radiographic
stage was evaluated also by the Steinberg classification.24
Exclusion criteria were patients with a surgical history on the
affected part, heavy smokers (Brinkman index> 600) requiring
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the continued use of warfarin, diabetes mellitus (defined by
HbA1c > 9.0%), arteriosclerosis obliterans, pregnancy, ma-
lignant disease, myocardial infarction, brain infarction,
rheumatoid arthritis, patients receiving dialysis, blood dis-
ease (leukemia, myeloproliferative disorder, and myelo-
dysplastic disorder), patients with a limited life expectancy,
hepatitis B, hepatitis C, human immunodeficiency virus and
syphilis, hypotension (systemic volume < 90mmHg), low
body weight ( < 40 kg), loss of marrow function (neutro-
phils < 1500/mm3, hemoglobin < 11.0 g/dL [men], 10.0 g/dL
[women], platelets < 100,000/mm3), patients whose drugs
(osteoporosis and steroids) were changed within 3 months
of the clinical study, and ineligible patients for the clinical
study as decided by a doctor.
Assessment of necrotic lesions
The necrotic lesion and the size were assessed by the
radiographic classification proposed by the Japanese In-
vestigation Committee.4 Type A lesions occupied the me-
dial one-third or less of the weight-bearing portion. Type B
lesions occupied the medial two-thirds or less of the weight-
bearing portion. Type C1 and type C2 lesions both occupied
more than the medial two-thirds of the weight-bearing
portion, wherein type C2 lesions extended laterally to the
acetabular edge, whereas type C1 lesions did not.4
Preparation of autologous bone marrow-derived MSC
Peripheral blood (400mL) was obtained from patients and
incubated at room temperature for 3 h to proceed coagulation.
Serum was then separated by centrifugation at 1500 g for
15min, collected, and stored at - 30C. This procedure was
repeated once after 7 days; therefore, autologous serum from
800mL was prepared from each patient.
The isolation of bone marrow-derived MSCs from patients
was performed as described previously.25 Briefly, bone
marrow (100mL) was aspirated under general anesthesia
from two sites of each right and left posterior iliac crest using
a bone marrow harvest needle (Angiotech, Gaineville, FL).
Aspirated bone marrow (25mL) was immediately mixed
with 1000 IU heparin (Mochida Pharmaceutical Co., Tokyo,
Japan) and transported to the cell processing center. Mono-
nuclear cells containing MSCs were seeded at a density of
2.5 · 105 cells/cm2and cultured with the a-minimal essential
medium with GlutaMAX (Invitrogen Co., Carlsbad, CA)
supplemented with 10% autoserum, 100U/mL penicillin, and
100mg/mL streptomycin, under 20% pO2 and 5% pCO2
conditions at 37C. When the total cell number reached
5.0 · 107, cells were dissociated by TripLE Select (Invitrogen
Co.), frozen with cryoprotectant (CP-1; Kyokuto Pharma-
ceutical Ind. Co., Tokyo, Japan), and stored in liquid nitro-
gen. Frozen cells were thawed and recultured at a density of
1.35 · 104 cells/cm2 under the same condition for 4 days
before transplantation surgery. The cells were dissociated by
TripLE Select, washed by serum, and prepared in suspension
2 h before transplantation. The survival rate was calculated
after thawing and at the timing of shipping.
Evaluation of multipotent MSCs
Differentiation potential. The potential for differentiation
in osteogenic, adipogenic, and chondrogenic directions was
examined as previously reported using the differentiation
induction protocol provided by Cambrex (East Rutherford,
NJ) in each MSC of the sampled cells from the preceding
MSC. Osteogenic differentiation was evaluated by Alizarin
Red S staining on day 14 of induction. Adipogenic differ-
entiation was evaluated by Oil Red O staining on day 21 of
differentiation, in which cells were stained with 40mM pH
4.2 Alizarin Red S (Sigma-Aldrich, St. Louis, MO). After 21
days of adipogenic differentiation, cells were stained with
0.3% Oil Red O (NacalaiTesque, Kyoto, Japan). After 21
days of chondrogenic differentiation, pellets were stained
with Alcian Blue (Muto Pure Chemicals Co., Ltd., Tokyo).
Cytogenetic analysis. G-band cytogenetic analysis was
performed on isolated mononuclear cells and a sample of final
transplanted MSCs. A minimum of 20 metaphases were ana-
lyzed in each case. The criteria used to describe a cytogenetic
clone and description of the karyotype followed the recom-
mendations of the International System for Human Cytoge-
netic Nomenclature.26
Measurement of endotoxin. The activity of endotoxin in
the supernatant of final transplanted MSCs was assayed by
the limulus test using the limulus ES-II single test kit
(Wako, Osaka, Japan).
In vivo tumor formation assays. Nonobese diabetic
(NOD)-severe combined immunodeficient (SCID) mice were
purchased from Shimizu Laboratory Supplies (Kyoto, Japan).
In vivo experiments were approved by the Institutional Animal
Research Committee, and were performed according to the
Guidelines for Animal Experiments of Kyoto University. A
fraction of final transplanted MSCs (5.0· 106) was sampled
and inoculated subcutaneously into the right flank of each
mouse. Tumor formation was monitored for 6 months, and
mice were then euthanized and the existence of tumors was
assessed.
Transplantation surgery
Patients were placed in a supine position on the table. A
curved skin incision (modified Smith-Peterson approach) was
prepared from the iliac crest to the anterior aspect of the
proximal thigh. The anterior aspect of the femoral neck was
explored and a cortical window (1.5· 4 cm) wasmade, through
which a bony trough connecting to the necrotic area was
formed under X-ray fluoroscopy.27,28 Necrotic areas, including
sclerotic bones, were extensively curetted under the fluoros-
copy and endoscopy. MSCs (0.5–1.5· 108) premixed with b-
tricalcium phosphate (b-TCP) granules (Osferion; Olympus
Terumo Biomaterials Co., Tokyo, Japan) were transplanted
into the cavity. The tricortical iliac bone (1.5· 2· 5 cm) with a
vascular pedicle (deep circumflex iliac vessels) was then har-
vested and grafted into the bone trough.27,28
Postoperative course
Patients were kept non-weight bearing for 6 weeks, fol-
lowed by partial bearing for the next 6 weeks. The return to
sports and work was allowed for the next 6 months con-
firming ossification. Clinical and radiological evaluations
were performed according to the protocol until 24 months
after surgery.
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Evaluation of treatment
The primary endpoint in this study was radiographic
progression of osteonecrosis by anteroposterior radiographs
at the point of pretreatment and 2 years after treatment.
Progression was evaluated according to the radiographic
clinical stage established by the SDIC with modifications to
the latest version of the ARCO staging system4 and Stein-
berg classification.24
Bone volume was calculated from CT images. CT images
consisted of 400 slices with a voxel size of 68.224mm in
all three axes. Coronal and sagittal cross-sectional views of
the femoral head were reconstructed using adjunctive soft-
ware. Image reconstruction and quantification of the femoral
head were performed with VG Studio MAX software (Ni-
hon Visual Science, Tokyo, Japan). The femoral head was
defined as an upper lesion on the line between the epiphysis
edge of the inside and outside. The bone volume of the
femoral head was calculated by VG Studio MAX software.
These radiographic results were evaluated by three outside
reviewers (two orthopedic surgeons and one radiologist)
who were unrelated to this clinical trial.
Clinical symptoms were evaluated by the hip score de-
fined by the Japanese Orthopaedic Association ( JOA).29
Adverse events
In this clinical trial, adverse events were defined as any
event occurred during the entire study period regardless of the
relationship with the protocol, and monitored in the Depart-
ment of Clinical Trial Design and Management, Translational
Research Center. Serious adverse events were assessed by the
External Data Monitoring Committee.
Statistical analysis
Continuous variables are described as the mean and
standard deviation. Radiographic progression of osteone-
crosis was assessed by the Wilcoxon’s signed-rank test.
Changes in bone volume and the clinical score according to
the JOA score were examined by the paired t-test. All re-
ported p-values were two sided, with a value below 0.05
being considered significant. All statistical analyses were
conducted in the Department of Clinical Trial Design and
Management, Translational Research Center using SAS
version 9.2 (SAS Institute, Cary, NC).
Results
Baseline data of patients
Between November 2007 and June 2009, 10 patients were
recruited into the clinical trial. All patients were male and
the average age was 31.7 (range 20–48) years, and previous
history of steroid treatment was found in four patients
(Table 1). The pretreatment radiographic stage was stage 3A
on six hips and stage 3B on four hips according to the SDIC
System, and stage 3 on six hips and stage 4 on four hips by
the Steinberg classification (Table 2). Pretreatment bone
volumes averaged 56.5 (range 45.3–66.4) cm3. Pretreatment
clinical scores according to the JOA averaged 65.6 (range
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Cell characteristics of manufactured MSCs
The preparation of autoserum and harvesting, culturing,
and storing of MSCs were safely conducted in all cases. The
number of isolated mononuclear cells from bone marrow
varied among cases (0.95–2.31 · 107/mL), with the expected
number of cells (5.0 · 107) being obtained within 10 days in
all cases, except for case 9, in which 16 days were required
(Table 1). The mean survival rate of frozen MSCs after
thawing was 93.6% (89.2–97.3%) (Table 1). The mean
population doubling and doubling time after thawing was
1.07 (0.41–1.68) and 106.4 h (57.2–232.1 h), respectively,
and the mean survival rate of shipping cells was 97.1%
(92.0–100%) (Table 1). The differentiation properties to the
osteogenic, adipogenic, and chondrogenic lineages were
confirmed in MSCs (data not shown). No tumorous condi-
tion was found in any SCID mice during the 6 months
following inoculation. A chromosomal aberration (46,XY,
add(1)(q11), - 2, - 4, add(7)(q11.1), - 22, + 3mar was de-
tected in one case (case 7, Table 1). An identical aberration
was found in BMCs immediately after they were isolated,
suggesting that this aberration may not have been related
to the in vitro culture process. Endotoxin activity was not
detected in the supernatant of MSCs.
Transplantation
During surgery, as much of the necrotic area was re-
moved as possible. The average bone defect was 9.3 cm3
(2.0–20.0 cm3). The average number of transplanted MSCs
was 1.2 · 108 (0.5–1.5· 108) and the average volume of
b-TCP granules was 3.3 g (1.5–5.0 g).
Radiographic progression of the stages
One patient who had bilateral lesions and decided to
receive surgery for contralateral hip joints was excluded
from this study, 12 months after the treatment. The other
nine patients completed the planned follow-up course and
were eligible for the evaluation. None of the stage 3A pa-
tients progressed to stage 3B or 4 (Figs. 1A and 2). Two hips
of stage 3B (50%) did not progress (Fig. 1A), while the
remaining two hips (50%) progressed to stage 4 twelve
months after the treatment (Fig. 1A).
According to the Steinberg classification, two of six hips
(33%) with stage 3 progressed to stage 4. One of four hips
(25%) with stage 4 progressed to stage 5 and one hip (25%)
progressed to stage 6. The remaining two hips (50%)
maintained the shape of the femoral head. The etiology of
the progressed hips was idiopathic in one hip and steroid
induced in one hip, and past illnesses of these cases were
meningioma in one hip and leukemia in one hip. Patient
ages were 48 and 38 years. The radiographic clinical clas-
sification was type C2 in both cases.
Changes in the bone volume
Bone volume of the femoral head according to CT was
evaluated before treatment, 1 year after treatment, and 2
years after treatment. Average bone volume before treat-
ment was 56.5 – 8.4cm3 (Fig. 1B). Average bone volume
significantly increased to 57.9 – 9.0 cm3 1 year after treat-
ment ( p = 0.005, Fig. 1B). Average bone volume maintained
at 57.7 – 10.6 cm3 2 years after treatment (Fig. 1B). How-
ever, bone volume decreased in progressed cases (43.6–
38.3 cm3 and 57.1–50.9 cm3, Table 2).
Clinical score
The clinical score according to the JOA was evaluated
before treatment, 1 year after treatment, and 2 years after
treatment. The average JOA score before treatment was
65.6 – 25.5 points (Fig. 1C). The JOA score significantly
improved to 90.2 – 14.1 points with statistic difference at
1 year after treatment (Fig. 1C). The JOA score maintained
at 87.9– 19.0 points 2 years after treatment ( p= 0.028,
Fig. 1C). The JOA score did not markedly improved in
progressed cases (36–39 and 84–84, Table 2).
Table 2. Radiological and Clinical Results
Stage


















1 C2 3B 3B 3 4 45.3 46.8 33 93
2 C2 3A 3A 3 3 65.4 68.8 96 100
3 C2 3B 4 4 5 43.6 38.3 36 39
4 C1 3A 3A 4 4 66.4 69.7 95 100
5 C2 3A 3A 3 3 58.3 60.2 79 95
6 C2 3A 3A 3 4 60.4 60.6 52 95
7 C2 3B 4 4 6 57.1 51.0 84 84
8 C2 3B 3B 4 4 56.0 58.0 56 90
9 C2 3A 3A 3 3 64.8 65.9 88 95
10 C2 3A NA 3 NA 47.4 NA 37 NA
aRadiographic clinical classification proposed by Japanese Investigation Committee.
bLatest modification of ARCO staging score by Japanese Investigation Committee.
cBone volume of femoral head calculated from computed tomography.
ARCO, Association Research Circulation Osseous; JOA, Japanese Orthopaedic Association; NA, not analyzed; Tx, treatment.
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Adverse events
Sixty-one adverse events were observed in ten patients
(Table 3). One serious adverse event was a case of medial
meniscus tear in the contralateral knee joint. An external
evaluation judged that this serious adverse event was not
correlated to the current clinical study. Remaining sixty ad-
verse events were nonserious adverse events. The frequently
reported adverse events were an increase in creatine phos-
phokinase, increase in C-reactive protein, anemia, pain in the
hip joint, decrease in albumin, complications at the wounded
area, decrease in total protein, wound pain, and fever (Table
3). In one case, the vascular pedicle of the transplanted bone
was injured during surgery, and the injured part of the vessels
was microsurgically replaced by vein grafts and its patency
was confirmed by a CT angiogram.
Discussion
The prognosis of ION is influenced by the size of the
necrotic area, stage of the disease, time from the diagnosis,
and etiological factors.4,9,30 According to the radiographic
classification proposed by the SDIC, types A and B are less
likely to progress to collapse than types C1 and C2.4,30
These results suggest that broad necrotic lesions on weight-
bearing areas increase the risk of disease progression. The
stage of disease is also an important factor that may influ-
ence the treatment.4,30 Core decompression surgery is
commonly used in precollapse stages such as stage 2. Based
on the clinical results reported by Hernigou, Gangji, and
Zhao, the combination of core decompression with in vitro
expanded MSCs was shown to be an appropriate approach
for stage 2 with lesions defined as class A or B.12,14,22
Application of the biomaterial as a scaffold of MSCs re-
ported by No¨th et al. may be an alternative choice for the
treatment of patients with this condition.31
Core decompression surgery was performed less than
vascularized bone graft surgery in the mild collapse stage
corresponding to a subchondral fracture (stage 3).32,33
Vascularized bone graft surgery has the benefits of sup-
plying living cells and mechanical strength. Kawate et al.
published a case report on cell therapy combined with
vascularized fibular grafts for ION.34 They cultured autol-
ogous MSCs with b-TCP granules in vitro, induced osteo-
genic differentiation and transplanted the necrotic area with
a vascularized fibular graft.34 In the present study, we used
undifferentiated MSCs instead of differentiated osteogenic
cells, which was based on the findings of our previous
preclinical study.23 A comparative study should be per-
formed to investigate which type of cell therapy is suitable
for the treatment of ION.
The safety and efficacy are critical points in any cell ther-
apy, and the major purpose of our study is also to evaluate
these points. As for the safety, we evaluated the characteristics
of cultured cells and adverse effects on patients during the
entire course of therapy. No serious events were observed in
any case during establishing and expanding cells such as
bacterial contamination. One serious risk of cell transplanta-
tion is the transformation during in vitro expansion.35 Previous
studies have described the spontaneous transformation of
MSCs during in vitro processing,36,37 which was shown to be
caused by contaminated cancer cells.38–40 This may happen in
laboratories in which cancer cells were cultured in the same
area. Cells for clinical use should be prepared in an area de-
fined by Good Manufacturing Practice, in which the culture of
other cells, particularly established cancer cells, should be
strictly forbidden.41 Cell transplantation in immunodeficient
mice is one of standard methods used to evaluate transfor-
mation,35 and we did not observe tumorous conditions in
NOD-SCID mice transplanted with MSCs in this series.
Chromosome analysis is another method that can predict
FIG. 1. Radiological and clinical results of treatment. (A)
Transition of the radiographic stage. The radiographic stage
of each case at the indicated time points was evaluated by
the system of Specific Disease Investigation Committee
(SDIC), which is a modified version of the system proposed
by the Association Research Circulation Osseous (ARCO)
Committee.4 One case of stage 3A before treatment was off-
protocol after 1 year. (B) Bone volume in the femoral head.
Bone volume in each femoral head was calculated from data
on computed tomography (CT) scans at each time point.
**p < 0.01. (C) Clinical results. Clinical results were eval-
uated by the Japanese Orthopaedic Association (JOA) hip-
score29 at each time point. **p < 0.01, * p< 0.05.
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transformation. Physiological stress during in vitro culture has
been suggested to induce chromosomal aberrations, which
may be the case even if the cell processing system is of a
clinical grade.42 In the present study, chromosomal aberra-
tions were not found in transplanted MSCs, except for one
case (case 7). This patient received intensive chemotherapy
for leukemia 13 years ago and was free from the disease at the
entry for the current study. The aberration was also detected in
BMCs before expansion, excluding the effect of culture pro-
cess. Cultured MSCs in this case showed no definite abnor-
malities during in vitro expansion or in their differentiation
properties. A careful long-term follow-up should be under-
taken in this case.
During the entire course, one serious and sixty adverse
events were observed (Table 3). There were two adverse
events correlated with cell preparation. One was vertigo (1/
10) after blood sampling for preparation of autoserum, and
the anemia (9/10) for preparation of autoserum and bone
marrow aspiration. One serious adverse event (knee me-
niscus tear) was evaluated not to be related to the clinical
study. Although it is difficult to completely deny the effect
of transplanted MSCs, almost all other adverse events were
those found in surgical procedures without cell transplan-
tation. For example, the increase of creatine phosphokinase
was almost always observed after the surgery involving
muscles, and in the current surgery, muscles attaching iliac
bone were severed for harvesting bone grafts. The increase
of C-reactive protein, anemia, and decrease in albumin and
total protein were also observed in major orthopedic sur-
geries. Without saying, even if the effect of adverse events
is minimum, it is rational to consider these adverse events
based on the risk–benefit balance. For example, we used
general anesthesia for harvesting bone marrow, which po-
tentially has a considerable risk. When the efficacy of the
current method is precisely evaluated, the risk associated
with each procedure should be reconsidered.
FIG. 2. Case presentation. A 33-year-old
man (case 9) with idiopathic osteonecrosis
of the femoral head. (A) Anteroposterior
radiographs of the femoral head before (a)
and 2 years after surgery (b). The radio-
graphic stage and classification before
treatment were 3A and type C2, respectively
(b). (B) Transverse CT image of the femoral
head before (a) and 2 years after treatment
(b). (C) Frontal view of the femoral head by
T1-weighted magnetic resonance imaging
before (a) and 2 years after treatment (b).
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Because of the small sample number and lack of control,
only limited information was obtained for efficacy in this
study. Two of nine cases in this study showed the pro-
gression of stages evaluated by the SDIC system. In both
cases, we observed the formation of cystic lesions in the
femoral head 12 months after surgery. b-TCP degradation
began from two to 3 weeks in vivo.43,44 An imbalance
between bone resorption and formation may cause such a
condition, and further study is required to define the suit-
able amount of b-TCP to be used in cell transplantation
therapy. We compared the current results with those of
simple vascularized iliac bone grafting performed during
1988 to 1997 in the affiliated hospital. The proportion of
nonprogressed case in that series was 26/38 (68%), while
the proportion of nonprogressed case in the current series
was 7/9 (78%, 95% CI: 40–97%). Although it is clear that
the prospective randomized trial using enough number of
patients is necessary to draw any conclusion, the result in
this study suggested the feasibility of our method. Based on
the results in this study, we re-evaluate the risk–benefit
value of each step and will modify to improve the value in
the next trials.
Whether transplanted cells exert therapeutic effects
through direct differentiation to osteogenic cells remain to
be investigated. Most initial cell transplantation studies
were designed and performed with the aim of engrafting
transplanted cells to regenerate the tissue. However, recent
studies showed that this was not the case. Only a small
proportion of MSCs, locally or systemically administrated,
will actually be incorporated into injured tissues, which
indicates that the beneficial effects of tissue repair and
regeneration are more likely indirect and depend on the
paracrine activity of MSCs.45,46 This should be also con-
sidered in our case, although it is difficult to trace the fate
of transplanted cells in humans.
As a conclusion, we showed that our procedure was
performed safely, but the efficacy was still to be determined.
In addition to the increase in the sample number, future
modification should be considered to increase the efficacy,
such as the combination with suitable degradable artificial
components and growth factors. Information from the cur-
rent clinical trial may lead to the successful result for the
advanced stage of ION.
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